Type 1 Alzheimer’s – Inflammatory

Posted on February 21st, 2017

Alzheimer’s disease (AD) is not one disease but more of a gradual change in many inputs – a network effect – similar to the downward slide a regional economy might experience during a recession. Alzheimer’s involves progressive neurodegeneration in the presence of misfolded proteins, poorly-understood inflammatory changes.  So, Alzheimer’s a uniquely personalized degenerative condition: genetically, clinically, and pathologically heterogeneous (Sudduth et al) [R]. One clear marker of of Alzheimer’s is high levels of inflammation comorbid with cognitive impairment (often referred to as “brain fog” in the young) advancing to intermittent amnesia leading to true dementia.

brain inflammation causes alzheimers

Inflammatory markers such as Phospho-tau and anti-amyloid-beta (Abeta) CSF levels are useful markers of neurodegeneration but not diagnostic of a process leading to neurodegeneration.

Indications of Inflammatory Alzheimer’s Disease

Systemic or Latent Infection is a Major Cause of Brain Inflammation and Alzheimer's Disease Systemic Infection is a Major Cause of Brain Inflammation and Alzheimer’s, Credit Nature Reviews

Lab Tests to Order

Identify Causes of Inflammation

Therapy Protocol

Please contact us for evidence-based personalization consultation.

References

  1. Mills, Charles. “M1 and M2 macrophages: oracles of health and disease.” Critical Reviews™ in Immunology 32.6 (2012). [R]
  2. Lai, M. K. P., et al. “Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex.” Neurology 57.5 (2001): 805-811. [R]
  3. Sudduth, Tiffany L., et al. “Neuroinflammatory phenotype in early Alzheimer’s disease.” Neurobiology of aging 34.4 (2013): 1051-1059. [R]
  4. Ship, Jonathan A., and Scott A. Puckett. “Longitudinal study on oral health in subjects with Alzheimer’s disease.” Journal of the American Geriatrics Society 42.1 (1994): 57-63. [R]
  5. Avagyan, Hripsime, et al. “Immune blood biomarkers of Alzheimer disease patients.” Journal of neuroimmunology 210.1 (2009): 67-72. [R]
  6. Sica, Antonio, and Vincenzo Bronte. “Altered macrophage differentiation and immune dysfunction in tumor development.” The Journal of clinical investigation 117.5 (2007): 1155-1166. [R]
  7. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue” Journal of Clinical Investigation 2003; 112:1796-808. [R]
  8. Gray, Seymour J., and ES Guzman Barron. “The electrophoretic analyses of the serum proteins in diseases of the liver.” Journal of Clinical Investigation 22.2 (1943): 191. [R]
  9. Kibrick, Andre C., and Alfred B. Clements. “A comparative study of the serum albumin-globulin ratio, the cephalin-cholesterol flocculation, and the thymol turbidity tests for liver function.” The Journal of laboratory and clinical medicine 33.6 (1948): 662-671. [R]
  10. Leonard, Brian E. “Inflammation, depression and dementia: are they connected?.” Neurochemical research 32.10 (2007): 1749-1756.  [R]
  11. Dantzer, Robert, et al. “From inflammation to sickness and depression: when the immune system subjugates the brain.” Nature reviews neuroscience 9.1 (2008): 46-56. [R]
  12. Honjo, Kie, Robert van Reekum, and Nicolaas PLG Verhoeff. “Alzheimer’s disease and infection: do infectious agents contribute to progression of Alzheimer’s disease?.” Alzheimer’s & Dementia 5.4 (2009): 348-360. [R]